Printer Friendly

BIOPLASTY SETTLES PATENT INFRINGEMENT SUIT

 BIOPLASTY SETTLES PATENT INFRINGEMENT SUIT
 ST. PAUL, Minn., July 24 /PRNewswire/ -- Bioplasty, Inc.


(NASDAQ-NMS: BIOP) announced today that it has settled the lawsuit brought by Collagen Corporation (NASDAQ: CGEN) alleging Bioplasty's Bioplastique(TM) and Macroplastique(TM) Macro Implant products infringed a Collagen U.S. patent. Pursuant to the terms of the settlement agreement and in return for a royalty, Bioplasty has maintained its right to manufacture, sell and market Bioplastique and Macroplastique throughout all domestic and foreign markets. Bioplastique is an injectable implant device designed to correct soft tissue defects in cosmetic and reconstructive plastic surgery applications, and Macroplastique is a similar product used to treat certain forms of urinary incontinence.
 Bioplasty, Inc. has more than 20 years of experience in the development, manufacturing and marketing of plastic surgery products worldwide. Bioplasty's stock is currently traded on NASDAQ National Market System under the symbol "BIOP."
 -0- 7/24/92
 /CONTACT: Timothy P. Lawin or Donald A. Major, 612-636-4112/
 (BIOP) CO: Bioplasty, Inc. ST: Minnesota IN: MTC SU:


AL -- MN003 -- 3029 07/24/92 12:24 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 24, 1992
Words:176
Previous Article:NATURAL EARTH TECHNOLOGIES ANNOUNCES 'GARDEN THUNDER LINE' TEST RESULTS
Next Article:PORT AUTHORITY TO GIVE PRESS TOUR OF VETPORT AT JFK AIRPORT
Topics:


Related Articles
INAMED BRINGS PATENT INFRINGEMENT SUIT AGAINST BIOPLASTY
BIOPLASTY, INC., ANNOUNCES RECEIPT OF PATENT INFRINGEMENT COMPLAINT
BIOPLASTY LICENSES SYNTHETIC WOUND CARE DRESSING
BIOPLASTY ANNOUNCES RESIGNATION OF CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD
BIOPLASTY AGREES TO PROPOSED SETTLEMENT OF SHAREHOLDERS' SUIT
BIO-VASCULAR REPORTS DISPUTE ON ROYALTIES
BIOPLASTY, INC. ANNOUNCES PROHIBITION OF SPIN OFF RECOMMENDED
BIOPLASTY SETTLES PATENT INFRINGEMENT SUIT
BIOPLASTY, INC. REACHES TENTATIVE AGREEMENT TO SETTLE SHAREHOLDERS' SUIT
BIOPLASTY, INC. FILES FOR PROTECTION UNDER CHAPTER 11 OF THE U.S. BANKRUPTCY CODE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters